Clinical development will be initiated in the first half of 2008.

Neogenix Oncology and Goodwin Biotechnology entered into an agreement for process development and manufacturing of Neogenix’ first therapeutic product. NPC-1C is a mAb intended for the treatment of advanced pancreatic cancer.


Neogenix expects to begin Phase I and Phase II trials of the product during the first half of 2008.

NewsAntibodies (Immune system)CancersClinical trialDigestive system cancerDrug research and developmentImmune componentImmunologyMedicine, Diagnosis, and TherapeuticsMonoclonal antibodiesPancreatic cancerPharmacologyPhase I clinical trials (Clinical trial)Phase II clinical trials (Clinical trial)Systemic conditions
Previous articleToyama Chemical Licenses RA Drug to Roche for Potentially More Than $370M
Next articleIntradigm Selects Agilent as Manufacturing Partner for RNAi Oncology Therapeutic
Also of Interest
Visual Proteomics: Observing Protein Location in Living Cells
Gene Network Interactions Shed Insight into Breast Cancer Onset and Development
Global Approach to Standardized Viral Vector Manufacturing
MilliporeSigma Launches All-in-One Genetic Stability Assay for Biosafety Testing
New Insights Could Boost Immunotherapy for Rare Eye Cancer
Skin in the Game: Oruka Takes on Blockbuster Drugs for Psoriasis, Dermatological Disorders
Related Media
AACR 2024: A Video Update from San Diego
Sickle Cell Salvation: The Victoria Gray Interview
Carl Icahn States His Case for Change at Illumina on "Close to the Edge"
Emerging Markets Collaborate to Succeed in Post-Pandemic World
Breathing Oxygen Back into the Biological Conversation
Global Single-Use Network Support Assurance of Supply